Anti-GBM disease - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: A1564E61534EEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Anti-GBM disease - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Anti-GBM disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Anti-GBM disease Understanding

The DelveInsight Anti-GBM disease epidemiology report gives a thorough understanding of the Anti-GBM disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anti-GBM disease in the US, Europe, and Japan. The report covers the detailed information of the Anti-GBM disease epidemiology scenario in seven major countries (US, EU5, and Japan).

Anti-GBM disease Epidemiology Perspective by DelveInsight

The Anti-GBM disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anti-GBM disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anti-GBM disease epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Anti-GBM disease Detailed Epidemiology Segmentation

The Anti-GBM disease epidemiology covered in the report provides historical as well as forecasted Anti-GBM disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Anti-GBM disease report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Anti-GBM disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Anti-GBM disease Epidemiology Report and Model provide an overview of the global trends of Anti-GBM disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Anti-GBM disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Anti-GBM disease
• The report provides the segmentation of the Anti-GBM disease epidemiology

Report Highlights

• 11-year Forecast of Anti-GBM disease epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Anti-GBM disease
• Cases of Anti-GBM disease by Mutation Types
• Anti-GBM disease Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anti-GBM disease?
• What are the key findings pertaining to the Anti-GBM disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Anti-GBM disease across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Anti-GBM disease?
• What are the currently available treatments of Anti-GBM disease?

Reasons to buy

The Anti-GBM disease Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Anti-GBM disease market
• Quantify patient populations in the global Anti-GBM disease market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anti-GBM disease therapeutics in each of the markets covered
• Understand the magnitude of Anti-GBM disease population by its epidemiology
• The Anti-GBM disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ANTI-GBM DISEASE

3. ANTI-GBM DISEASE: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Anti-GBM disease Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Anti-GBM disease Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Anti-GBM disease Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Anti-GBM disease Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Anti-GBM disease Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Anti-GBM disease Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Anti-GBM disease Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Anti-GBM disease Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Anti-GBM disease Treatment and Management
6.2. Anti-GBM disease Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Anti-GBM disease Epidemiology in 7MM (2019-2032)
Table 2: Anti-GBM disease Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Anti-GBM disease Epidemiology in the United States (2019-2032)
Table 4: Anti-GBM disease Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Anti-GBM disease Epidemiology in Germany (2019-2032)
Table 6: Anti-GBM disease Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Anti-GBM disease Epidemiology in France (2019-2032)
Table 8: Anti-GBM disease Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Anti-GBM disease Epidemiology in Italy (2019-2032)
Table 10: Anti-GBM disease Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Anti-GBM disease Epidemiology in Spain (2019-2032)
Table 12: Anti-GBM disease Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Anti-GBM disease Epidemiology in the United Kingdom (2019-2032)
Table 14: Anti-GBM disease Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Anti-GBM disease Epidemiology in Japan (2019-2032)
Table 16: Anti-GBM disease Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Anti-GBM disease Epidemiology in 7MM (2019-2032)
Figure 2 Anti-GBM disease Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Anti-GBM disease Epidemiology in the United States (2019-2032)
Figure 4 Anti-GBM disease Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Anti-GBM disease Epidemiology in Germany (2019-2032)
Figure 6 Anti-GBM disease Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Anti-GBM disease Epidemiology in France (2019-2032)
Figure 8 Anti-GBM disease Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Anti-GBM disease Epidemiology in Italy (2019-2032)
Figure 10 Anti-GBM disease Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Anti-GBM disease Epidemiology in Spain (2019-2032)
Figure 12 Anti-GBM disease Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Anti-GBM disease Epidemiology in the United Kingdom (2019-2032)
Figure 14 Anti-GBM disease Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Anti-GBM disease Epidemiology in Japan (2019-2032)
Figure 16 Anti-GBM disease Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report